Colesevelam
- Generic Name
- Colesevelam
- Brand Names
- Cholestagel, Lodalis, Welchol
- Drug Type
- Small Molecule
- CAS Number
- 182815-43-6
- Unique Ingredient Identifier
- 1XU104G55N
- Background
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
- Indication
用于以胆固醇升高为主的高脂血症，当饮食和锻炼不能良好达到效果者，可单独使用或与他汀类合用。
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02952963
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, DK, Denmark
Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Severe Obesity
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02876484
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Randomized Trial Comparing Colesevelam vs. Ezetimibe
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02682680
- Locations
- 🇨🇦
LMC Barrie, Barrie, Ontario, Canada
🇨🇦LMC Brampton, Brampton, Ontario, Canada
🇨🇦LMC Calgary, Calgary, Alberta, Canada
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 282
- Registration Number
- NCT02637557
- Locations
- 🇺🇸
IW-3718 Investigator, Lynchburg, Virginia, United States
A Study of Colesevelam in Fecal Incontinence
- Conditions
- Fecal IncontinenceBile Acid Malabsorption
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 88
- Registration Number
- NCT02628626
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
- Conditions
- Multiple Myeloma
- Interventions
- Other: Serum-derived bovine immunoglobulin/protein isolate (SBI)Other: Double Placebo
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT02619812
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
- Conditions
- Diarrhea Predominant Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT02111603
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT02050074
- Locations
- 🇩🇰
Diabetes Research Division, Department of Medicine, Gentofte Hospital, Hellerup, Copenhagen, Denmark
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT02030925
- Locations
- 🇺🇸
Ironwood Investigational Site, South Ogden, Utah, United States
Effects of Fish Oil and Colesevelam (STAIR7007)
- Conditions
- Sitosterolemia
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 13
- Registration Number
- NCT01948648
- Locations
- 🇨🇦
Richardson Center for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.